

**REMARKS**

**I. STATUS OF THE CLAIMS AND FORMAL MATTERS**

Claims 1-14 are now pending in the present application.

Applicants thank the Examiner for noting that the claims required correction to comply with U.S. practice. Claims 1-14 have been amended accordingly and now all recite methods of treatment.

No new matter has been introduced.

**II. RESTRICTION REQUIREMENT**

The October 31, 2008 Office Action called for restriction from among the following:

- I. Claims 1-14, drawn to a method of manufacturing 2,5-dihydroxybenzenesulfonic acid or any of its pharmaceutically acceptable salts.
- II. Claims 1-14, drawn to a method of treatment comprising 2,5-dihydroxybenzenesulfonic acid or any of its pharmaceutically acceptable salts.
- III. Claims 1-14, drawn to a process of preparing 2,5-dihydroxybenzenesulfonic acid or any of its pharmaceutically acceptable salts.
- IV. Claims 1-14, drawn to a composition, comprising 2,5-dihydroxybenzenesulfonic acid or any of its pharmaceutically acceptable salts.

Applicants elect Group II, claims 1-14, which are directed to methods of treatment comprising 2,5-dihydroxybenzenesulfonic acid or any of its pharmaceutically acceptable salts.


**CONCLUSION**

Early and favorable consideration of the application on the merits, and early Allowance of the application are earnestly solicited.

The Commissioner is authorized to charge any fee occasioned by this paper, or credit any overpayment in fees, to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By:



Sandra Kuzmich, Ph.D.

Reg. No. 46,117

Kathleen N. Ehrhard, Ph.D.

Reg. No. 55,144

Tel.: (212) 588-0800

Fax: (212) 588-0500